ATEC
failedAlphatec Holdings, Inc.
Price Chart
Gap Information
Score Analysis
Model 1: Rerate Score
Model 2: Trade Probability
AI Thesis
Alphatec Holdings (ATEC) is a spine surgery technology company that has been executing a multi-year turnaround under management focused on disrupting the traditional spine market with workflow-integrated solutions. A 5% gap-up on 1.7x average volume post-earnings signals a meaningful positive reaction from institutional investors, likely driven by revenue growth acceleration, progress toward profitability, or updated guidance that exceeded conservative Street models. The stock gapping above $10 from a $9.52 base, while sitting above its 50-day SMA ($8.63), suggests the market is beginning to price in improved fundamentals rather than just short-covering or noise. The key re-rating thesis for ATEC revolves around its ability to continue taking share in the $10B+ global spine market through its differentiated technology platform. If this quarter demonstrated sustained revenue growth in the high-teens to 20%+ range, gross margin expansion, and a credible path to positive adjusted EBITDA, Wall Street would likely begin modeling earlier profitability — compressing the risk premium and expanding the multiple. Spine medtech is a sector where even modest acceleration can trigger significant rerating because the addressable market is large and competitive displacement is sticky once surgeons adopt new systems.
Analyzed by rerate-v2+glm-5.2 · Aug 4, 2026
Catalysts
- Revenue growth exceeding 18-20% year-over-year, indicating market share gains in spine surgery
- Gross margin expansion toward 70%+ as manufacturing scales and product mix improves
- Clear pathway to adjusted EBITDA breakeven or profitability within 12-18 months
- New product launches or FDA clearances expanding the technology portfolio
- International revenue growth or new geographic market penetration
- Large surgeon adoption metrics showing accelerating utilization rates
Risks
- Continued cash burn requiring additional capital raises or dilutive equity issuance
- Intense competition from larger spine players (Medtronic, Stryker, Globus Medical) with deeper resources
- Slowing procedure volumes or pricing pressure in the U.S. spine market
- Reimbursement environment changes affecting surgeon adoption economics
- Execution risk on new product commercialization and surgeon training pipeline
- Potential for quarterly volatility — spine device sales can be lumpy and seasonally weak in Q1
Technical Setup
Forward Returns
Outcomes calculated Aug 11, 2026
Post-Gap Validation — 5-Day Follow-Through
Day-by-Day Price Action
| Day | Close | High | Low | Volume |
|---|---|---|---|---|
| 📍 Day 1 | $9.57 | $10.10 | $9.26 | 5.22M |
| Day 2 | $9.21 | $9.64 | $8.90 | 3.70M |
| Day 3 | $9.31 | $9.34 | $9.05 | 2.41M |
| Day 4 | $9.49 | $9.53 | $9.10 | 1.97M |
| Day 5 | Pending | |||
Signal Breakdown
Gap 100% filled — price gave back most of the post-earnings gap
Volume dropped 62% from day 1 — no institutional follow-through buying
Lower highs with peak close on day 1 — price action suggests distribution, not accumulation
Drew down 12.3% from gap close — significant give-back
No fundamental data to evaluate beat quality
Analysis updated Aug 11, 2026